tbuckley/cabot-search huggingface dataset:
Abstract O.33: Identification of Kawasaki Disease-specific Molecules in the Sera as Microbe-associated Molecular Patterns
Authors: Takeshi Kusuda, Yasutaka Nakashima, Kenji Murata, Shunsuke Kanno, Yumi Mizuno, Kazunobu Ouchi, Kenji Waki, Toshiro Hara
Journal: Circulation (2015)

Background: Kawasaki disease (KD) is a systemic vasculitis of unknown etiology. The innate immune system is involved in its pathophysiology at the acute phase. We have recently established a novel murine model of KD coronary arteritis by oral administration of a synthetic microbe-associated molecular pattern (MAMP). On the hypothesis that specific MAMPs exist in KD sera, we have searched them to identify KD-specific molecules and to assess the pathogenesis. Methods: The study subjects included 117 patients with KD (median age, 21 months; range 3-96 months; male/female, 65/52) and 101 controls with other febrile illnesses (DC: median age, 16 months; range 0-121 months; male/female, 61/40), and 5 normal controls (NC: median age, 6 months; range 3-39 months; male/female, 1/4). We performed liquid chromatography-mass spectrometry (LC-MS) analysis of fractionated serum and microbial samples by ethyl acetate. Results: KD serum samples elicited proinflammatory cytokine responses from human coronary artery endothelial cells (HCAECs). By LC-MS analysis of KD serum samples collected at 3 different periods, we detected a variety of KD-specific molecules in the lipophilic fractions that showed distinct m/z and MS/MS fragmentation patterns in each cluster. Serum KD-specific molecules showed m/z and MS/MS fragmentation patterns almost identical to those of MAMPs obtained from Bacillus cereus, Yersinia pseudotuberculosis and Staphylococcus aureus at the 1st study period, and from MAMPs from Bacillus cereus, Bacillus subtilis/Bacillus cereus/Yersinia pseudotuberculosis and Staphylococcus aureus at the 2nd and 3rd periods. These molecules decreased after intravenous immunoglobulin (IVIG) treatment. Conclusions: We herein conclude that serum KD-specific molecules possess molecular structures common to MAMPs from Bacillus cereus, Bacillus subtilis, Yersinia pseudotuberculosis and Staphylococcus aureus. Discovery of these KD-specific molecules offers novel insight into the diagnosis and management of KD as well as its pathogenesis.
THE EFFECT OF CALCIUM CHANNEL BLOCKER ON Tc-99m PYROPHOSPHATE SCANS IN INFARCTED DOGS.
Authors: J. Jacobs, N. Alazraki, R. Safarian, K. Murphy, B. Baker, L. Peric-Golia
Journal: Clinical Nuclear Medicine (1983)

Jacobs, J.; Alazraki, N.; Safarian, R.; Murphy, K.; Baker, B.; Peric-Golia, L. Author Information
Critique and Cavil
Authors: George X. Trimble
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PREVENTION OF COLDS BY ULTRAVIOLET RADIATION
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pinpointing the cause of mucus production
Authors: T. Ziporyn
Journal: JAMA (1981)

Bronchorrhea has tormented millions of patients with allergies, asthma, and associated diseases. Now, a team of researchers at the National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md, thinks it may at last have found the culprit. According to Michael Kaliner, MD, director of the Allergic Diseases Center at the NIAID, recent experiments on tissue cultures of human lung indicate that the agents of mucus release in these tissues may be the hydroxyeicosatetraenoic acids (HETEs), which are metabolic by-products of arachidonic acid, a major precursor of prostaglandins. Kaliner and colleagues Zvi Marom, MD, James H. Shelhamer, MD, and Frank Sun, PhD, studied the relationship between prostaglandins, arachidonic acid, and mucus secretion by measuring the quantity of<sup>3</sup>H-glucosamine-labeled mucus glycoproteins released when human bronchial tissue cultures were subjected to various stimuli. They did these studies because earlier findings had indicated that levels of all prostaglandins increased in human lung
Ankle/arm blood pressure index. A useful test for clinical practice?
Authors: W. B. Applegate
Journal: JAMA (1993)

A basic problem facing the clinician who practices primary prevention of coronary heart disease (CHD) through risk factor modification is that, unless the baseline risk is high, relatively large numbers of patients must undergo risk factor modification to prevent CHD events in a relative few.<sup>1</sup>This is particularly a problem for women 45 to 70 years of age. Since the prevalence of CHD is lower in these women, risk factors are moderately less predictive of future CHD events than they are for men.<sup>2</sup>For these reasons special emphasis is usually placed on risk stratification (presence of multiple CHD risk factors or evidence of end-organ damage or previous vascular morbid events) to indicate which patients should undergo more aggressive risk factor alteration. Now it appears that a relatively simple office procedure involving measurement of the ankle/arm systolic blood pressure index (AAI), which is known to correlate with the presence
Formation, Occurrence and Analysis of Polychlorinated Dibenzofurans, Dioxins and Related Compounds
Authors: Hans-Rudolf Buser
Journal: Environmental Health Perspectives (1985)

In several accidents (fires, explosions) involving electrical systems containing polychlorinated biphenyls (PCBs) or benzenes (PCBZs), the formation of polychlorinated tricyclic aromatic compounds such as polychlorinated dibenzofurans (PCDFs), dibenzo-p-dioxins (PCDDs) and biphenylenes (PCBPs) was observed. These findings were not surprising in light of our previous studies on the formation of PCDFs and PCDDs from the thermolysis (500-750 degrees C in presence of air) of PCBs or PCBZs. In these experiments we identified three main and a fourth minor reaction pathway leading to PCDFs from PCBs. The three main reactions involved the loss of ortho-Cl2, and the losses of ortho-HCl with and without a 2,3-chlorine shift. The fourth, minor reaction route found with some PCBs, involved the loss of ortho-H2. These reaction pathways were intramolecular cyclizations via oxidation to phenolic compounds. Thermolysis of commercial PCBs (Aroclor 1254 and 1260) yielded the same PCDF isomers as expected from the main PCB components via these four reaction pathways; the isomers formed included the toxic 2,3,7,8-substituted tetra-, penta- and hexa-CDFs. Thermolysis of PCBZs involved complex condensation reactions with multiple rearrangements leading to PCDFs as well as PCDDs. Again oxidation to phenolic products was involved but the reaction routes are not yet fully elucidated. The results of samples from transformer and capacitor accident sites showed very complex PCDF mixtures with 2,3,7,8-substituted isomers as main components and originating from the PCBs in the transformer liquid. The unusual presence of PCDDs in samples from the Binghamton accident originates from PCBZs present in transformer fluid of that specific installation, thus confirming our previous thermolysis findings.(ABSTRACT TRUNCATED AT 250 WORDS)
Age-Adjusted Recipient Pre-Transplant Telomere Length and Treatment Related Mortality After Hematopoietic Stem Cell Transplantation
Authors: Régis Peffault de Latour, Rodrigo T. Calado, Marc Busson, Jeffrey Abrams, Marie Robin, Jérome Larghero, Nathalie Dhedin, Emmanuel Clave, Antoine Toubert, Pascale Loiseau, Gerard Socie, Neal S. Young
Journal: Blood (2011)
Medical News
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: Takayoshi Ohkubo, Masahiro Kikuya, Hirohito Metoki, Kei Asayama, Taku Obara, Junichiro Hashimoto, Kazuhito Totsune, Haruhisa Hoshi, Hiroshi Satoh, Yutaka Imai
Journal: Journal of the American College of Cardiology (2006)
Securinine
Authors: Reuben Copperman
Journal: JAMA (1974)

<h3>To the Editor.—</h3> In December 1971, E. G. Dimond made reference to research in China on the use of securinine in the treatment of poliomyelitis (218:1552, 1971). Spurred by this reference, we obtained a small amount of the drug and treated one case of amyotropic lateral sclerosis (ALS) with securinine (<i>Pa Med</i>76:36, 1973). Subsequently, with the permission of the Food and Drug Administration (<i>IND</i>8929), the drug was administered to eight additional patients, affording us sufficient experience to report our impressions. We do not believe that securinine has any significant effect on the progression of ALS. Not one of our patients experienced a remission, nor did any of our patients show a substantial slowing of the rate of progression. In this respect, our experience probably is in agreement with what must have been the negative experience of the Russian investigators who discovered the drug and who make no reference
The Menopause; a Consideration of the Phenomena which Occur to Women at the Close of the Child-bearing Period, with Incidental Allusions to their Relationship to Menstruation; also a Particular Consideration of the Premature (especially the Artificial) Menopause
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with &gt; 25% bone marrow involvement
Authors: J. Mones, M. Coleman, L. Kostakoglu, J. M. Fiore, D. Muss, R. Furman, P. Stewart, S. Kroll, S. J. Goldsmith, J. P. Leonard
Journal: Journal of Clinical Oncology (2004)

6575 Introduction: The Bexxar therapeutic regimen can produce durable and complete responses in patients with relapsed/refractory low-grade NHL. Virtually all previous studies of radioimmunotherapeutic agents (including Bexxar therapy) for NHL excluded patients with extensive bone marrow involvement (BMI) with tumor (>25% intertrabecular space) due to risk of excess hematologic toxicity. Therefore, we evaluated Bexxar therapy specifically in this patient population to assess safety and toxicity in a dose-escalation study. Methods: Subjects were required to have baseline BMI of >25% and platelet count of 150,000/mm3. A patient-specific dose of Iodine 131 Tositumomab was administered to deliver a defined amount of total body radiation. Dose escalation began at a total body dose of 45 cGy (subsequently increased in increments of 10 cGy). Dose limiting toxicity (DLT) was defined as ANC < 500/mm3 or platelets <25,000/mm3 for >17 d; or ANC <750/mm3 or platelets <50,000/mm3 for >24 d. Results: Eleven patients were enrolled (8 at 45 cGy and 3 at 55 cGy). Estimated BMI was 30% to 65%, with median of approx 40%. Subjects had a median of 3 prior chemotherapies (range: 1–6). One of 6 evaluable patients treated at 45 cGy experienced hematologic DLT. Three patients (estimated BMI 40–60%) received 55 cGy, with 1 having hematologic DLT concurrent with lymphoma progression with extensive BMI. Three of 11 (27%) subjects received hematologic supportive care. Non-hematologic toxicities were minimal and were similar to previous studies. Two patients responded with durations of 1 and 43.6+ months. Conclusion: Treatment of patients with >25 % bone marrow involvement with Bexxar therapy was well tolerated at 45 cGy total body dose and can result in lymphoma responses. Further studies with additional patients and at higher doses are required to further characterize the MTD and to establish efficacy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Corixa Corp. Corixa Corp. Corixa Corp. Corixa Corp.
Senile Freckles
Authors: William B. Bean
Journal: JAMA (1975)

I DO NOT share the wry notions of the younger generation that the world began the day they were born, or that they invented sex. But the mere fact of having been around for a long time brings concerns and problems. I deal with one of the simpler ones—splotches, freckles, and old-age marks. Few people ever think of freckles as badges of distinction that are achieved with maturity and overmaturity. Such are the freckles of age. They are called<i>lentigo senilis</i>in the loud, barbed enthusiasm of our dermatologic brethren. Age has its compensations, but most of us would agree that wisdom has not ruffled the surface of the large seas of ignorance that surround the topic of senile freckles. Fortunately, an occasional person who grows old grows wise, too. These little, brown, blotchy, flat marks are found in most people when they are middle-aged, whether they admit it—or them—or
From science to practice. Meta-analyses using individual patient data are needed
Authors: A. D. Oxman
Journal: JAMA (1995)

In this issue ofTHE JOURNAL, Jeng et al<sup>1</sup>report discrepancies between the results of meta-analyses using aggregate data available from the literature (MAL) and meta-analyses using individual patient data (MAP). This may be seen as further grounds for mistrusting meta-analysis in general<sup>2,3</sup>and MAL in particular,<sup>4</sup>but before deciding that all meta-analyses are an exercise in "mega-silliness,"<sup>5</sup>consider the alternatives. See also p 830. The key characteristic of MAPs is the use of individual patient data (IPD). Meta-analyses using aggregate data also can, and frequently do, include unpublished data, so the term<i>IPD meta-analyses</i>is preferable to avoid confusing issues relating to using IPD and issues relating to using unpublished data. IPD meta-analyses require international cooperation between the individuals and groups who have conducted relevant trials and a considerable amount of time, personnel, and financial resources.<sup>6</sup>These global collaborative endeavors have yielded important information
Dermatographia
Authors: Max Grolnick
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Your editorial, "Skin-Writing" (<b>203</b>:883, 1968), was based on the article, "Dermatographia: A Critical Review," which appeared in the<i>Annals of Allergy</i>issue of October 1967, under the authorship of Melvyn R. Ostrov, MD. In a Letter to the Editor of the<i>Journal of Allergy</i>for April 1968, Dr. Ostrov stated: "the name of Max Grolnick, MD, F.A.C.A., should have been included as coauthor. This omission constitutes an error which demands public correction...." Obviously your editorial writer could not have known this, but I hopeThe Journalwill take notice of this failure to include my name in the authorship of the paper.
Fatal Infection in Infant Associated with Coxsackie A-16 Virus
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Low dose liposomal amphotericin B seems to be effective against visceral leishmaniasis
Journal: BMJ (2001)

Low dose liposomal amphotericin B seems to be effective against visceral leishmaniasis Low dose liposomal amphotericin B given as a single dose or short five day course seems effective against visceral leishmaniasis in India.Recommended regimens of liposomal amphotericin are prohibitively expensive in developing countries, but in a pilot study on 91 patients, Sundar et al (p 419) found cure rates of 92% with a dose of 5 mg/kg given either as a single infusion or over five days.If proved effective in larger trials, low dose regimens should help make the drug more affordable.
THE NATION AT WAR
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Axis Label in Figure
Authors: Pamela Lutsey, Faye Norby, Alvaro Alonso
Journal: JAMA Internal Medicine (2020)

J. Ariana Noel, MD; Sarah E. Bota, BSc; William Petrcich, MSc; Amit X. Garg, MD; Juan Jesus Carrero, PhD; Ziv Harel, MD; Navdeep Tangri, MD; Edward G. Clark, MD; Paul Komenda, MD; Manish M. Sood, MD
WORK AT THE SMALLPOX LABORATORY IN CLEVELAND.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal